WO2008130321A3 - Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain - Google Patents

Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain Download PDF

Info

Publication number
WO2008130321A3
WO2008130321A3 PCT/SE2008/050460 SE2008050460W WO2008130321A3 WO 2008130321 A3 WO2008130321 A3 WO 2008130321A3 SE 2008050460 W SE2008050460 W SE 2008050460W WO 2008130321 A3 WO2008130321 A3 WO 2008130321A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclyl
tetrahydronaphtalene
chromane
pain
novel
Prior art date
Application number
PCT/SE2008/050460
Other languages
French (fr)
Other versions
WO2008130321A2 (en
Inventor
Yevgeni Besidski
Inger Kers
Istvan Macsari
Martin Nyloef
Didier Rotticci
Original Assignee
Astrazeneca Ab
Yevgeni Besidski
Inger Kers
Istvan Macsari
Martin Nyloef
Didier Rotticci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Yevgeni Besidski, Inger Kers, Istvan Macsari, Martin Nyloef, Didier Rotticci filed Critical Astrazeneca Ab
Publication of WO2008130321A2 publication Critical patent/WO2008130321A2/en
Publication of WO2008130321A3 publication Critical patent/WO2008130321A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The present invention relates to new compounds. The present invention relates to new compounds, to pharmaceutical composition containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof.
PCT/SE2008/050460 2007-04-23 2008-04-22 Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain WO2008130321A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91331407P 2007-04-23 2007-04-23
US60/913,314 2007-04-23

Publications (2)

Publication Number Publication Date
WO2008130321A2 WO2008130321A2 (en) 2008-10-30
WO2008130321A3 true WO2008130321A3 (en) 2008-12-18

Family

ID=39876088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2008/050460 WO2008130321A2 (en) 2007-04-23 2008-04-22 Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain

Country Status (1)

Country Link
WO (1) WO2008130321A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
WO2016033105A1 (en) 2014-08-29 2016-03-03 The Board Of Regents Of The University Of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
CA3108792A1 (en) 2018-09-10 2020-03-19 Kaken Pharmaceutical Co., Ltd. Novel heteroaromatic amide derivative and medicament containing the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034883A1 (en) * 1996-03-22 1997-09-25 Astra Aktiebolag Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO1999005134A1 (en) * 1997-07-25 1999-02-04 Astra Aktiebolag Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO1999014212A1 (en) * 1997-09-18 1999-03-25 Astrazeneca Ab Substituted chroman derivatives
WO1999014213A1 (en) * 1997-09-18 1999-03-25 Astrazeneca Ab Substituted chroman derivatives
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US20060025415A1 (en) * 2003-08-08 2006-02-02 Gonzalez Jesus E Iii Compositions useful as inhibitors of voltage-gated sodium channels

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034883A1 (en) * 1996-03-22 1997-09-25 Astra Aktiebolag Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO1999005134A1 (en) * 1997-07-25 1999-02-04 Astra Aktiebolag Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO1999014212A1 (en) * 1997-09-18 1999-03-25 Astrazeneca Ab Substituted chroman derivatives
WO1999014213A1 (en) * 1997-09-18 1999-03-25 Astrazeneca Ab Substituted chroman derivatives
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US20050137190A1 (en) * 2003-08-08 2005-06-23 Gonzalez Jesus E.Iii Compositions useful as inhibitors of voltage-gated sodium channels
US20060025415A1 (en) * 2003-08-08 2006-02-02 Gonzalez Jesus E Iii Compositions useful as inhibitors of voltage-gated sodium channels

Also Published As

Publication number Publication date
WO2008130321A2 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
IL225198A (en) Aminotetrahydropyran compounds, pharmaceutical compositions comprising the same and the use thereof for the treatment of diabetes
TW200745122A (en) New compounds I
MX2009006704A (en) New compounds.
HK1146485A1 (en)
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
EP2305640A3 (en) Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
TW200606162A (en) Pyrazolopyridine derivatives
WO2009153496A3 (en) Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia
HK1166983A1 (en) Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
PT1778680E (en) Spirocyclic cyclohexane derivatives
TW200621690A (en) Novel compounds
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
UA96447C2 (en) Polymorph forms of (2s)-(4e)-n-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
ZA201003794B (en) Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation
WO2007130821A3 (en) Mglur5 modulators ii
CL2008000982A1 (en) COMPOUNDS DERIVED FROM 5-OXO-ISOXAZOL-CARBOXAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF METABOLISM OF
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
TW200745133A (en) New compounds II
WO2008130319A3 (en) Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08779261

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08779261

Country of ref document: EP

Kind code of ref document: A2